Status:
COMPLETED
COVID-19 Seroprevalence Study in French Guiana
Lead Sponsor:
Institut Pasteur
Collaborating Sponsors:
Institut Pasteur de la Guyane
Laboratoire de biologie médicale, Institut Pasteur de la Guyane
Conditions:
Coronavirus Infection
Severe Acute Respiratory Syndrome
Eligibility:
All Genders
Phase:
NA
Brief Summary
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the...
Detailed Description
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the...
Eligibility Criteria
Inclusion
- Person going to a prevention and care center or medical biology analysis laboratory as part of the care, regardless age, regardless of an acute or previous infection with COVID-19;
- State of health compatible with a blood sample as defined in the protocol
Exclusion
- Inability to consent
- Person under guardianship or curatorship
- Known pathology or a health problem contraindicated with the collect of blood sample.
Key Trial Info
Start Date :
July 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 24 2021
Estimated Enrollment :
3541 Patients enrolled
Trial Details
Trial ID
NCT04490850
Start Date
July 15 2020
End Date
September 24 2021
Last Update
February 15 2022
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Andrée Rosemon
Cayenne, French Guiana
2
Laboratoire de biologie méicale, Institut Pasteur de la Guyane
Cayenne, French Guiana
3
Laboratoires Eurofins Guyane
Cayenne, French Guiana
4
Laboratoire de biologie médicale de Kourou
Kourou, French Guiana